SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-004693
Filing Date
2022-02-11
Accepted
2022-02-11 08:30:43
Documents
16
Period of Report
2022-02-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 KTRA-8-K Q2 FS 20211231 ktra-8k_20220211.htm   iXBRL 8-K 47592
2 EX-99.1 ktra-ex991_6.htm EX-99.1 113296
3 GRAPHIC gat4fjkh3fed000001.jpg GRAPHIC 5293
4 GRAPHIC gvzjaj0io22p000001.jpg GRAPHIC 115441
5 GRAPHIC gat4fjkh3fed000002.jpg GRAPHIC 5293
  Complete submission text file 0001564590-22-004693.txt   475976

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ktra-20220211.xsd EX-101.SCH 5689
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ktra-20220211_lab.xml EX-101.LAB 19431
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ktra-20220211_pre.xml EX-101.PRE 11579
10 EXTRACTED XBRL INSTANCE DOCUMENT ktra-8k_20220211_htm.xml XML 3534
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

IRS No.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 22616903
SIC: 2834 Pharmaceutical Preparations